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GASTROENTEROLOGY & HEPATOLOGY

Diagnosing Non-HFE Hereditary Hemochromatosis
Brian Park, MD, Naman Upadhyay, MD, Dina Halegoua-Demarzio, MD

ABSTRACT
Non-HFE hemochromatosis is a rare cause of end stage
liver dysfunction that is characterized by excessive iron
deposition in the liver. The vast majority of primary iron
overload is due to well documented mutations of the
HFE genetic locus, however, rare genetic cases not
involving the HFE locus have been documented. Here
we present the case of a 63-year-old female who
developed liver failure due to non-HFE hemochromatosis. Secondary causes of iron overload were ruled
out, and genetic testing was negative for primary HFE
(C282Y and H63D) mutations. We discuss the clinical
work up involved in making the diagnosis of non-HFE
hemochromatosis and the treatment options.
Keywords: Non-HFE Hemochromatosis, primary
hemochromatosis, iron overload, hereditary hemochromatosis

INTRODUCTION
Hereditar y Hemochromatosis (HH) is a disease
characterized by increased intestinal absorption of iron
and subsequent deposition in tissues. Hemochromatosis
is a progressive disease that without therapeutic
intervention can lead to iron accumulation in tissues
leading to organ damage such as liver cirrhosis, diabetes,
skin discoloration, and cardiomyopathy1.
Primary hemochromatosis due to the HFE gene is the
most common identified genetic disorder in Caucasians
of northern European descent with a prevalence of 1 in
200 individuals and accounting for 60-95% of European
iron overload cases2. In contrast, most cases of iron
overload that do not involve the HFE gene are due to
secondary hemosiderosis. However, there are rarely
observed gene mutations that result in primary
hemochromatosis collectively called non - HFE
hemochromatosis3.

CASE REPORT
A 63-year-old Caucasian female presented for evaluation
of abnormal bile duct appearance on ERCP after being
diagnosed with gallstone pancreatitis, duodenal ulcers
and gastritis at another hospital. Over the past several
years she had noticed increasing fatigue, unintentional
weight gain of 30 pounds, lower extremity and abdominal
swelling. The patient recalls having jaundice at the age of
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14, and at age 28 she was told she had hepatitis although
her hepatitis testing was negative. She has a history of
psoriasis and vitiligo. Her family history is notable for liver
disease of unknown etiology in her grandmother,
gallbladder and thyroid disease in her mother, daughter
with psoriasis, and son with type 1 diabetes mellitus.
She rarely drinks alcohol. She has taken an occasional
Aleve for arthritic pains but had not taken any NSAIDs in
two years. She does not smoke cigarettes or use illicit
drugs. She worked at a large wholesale grocery as a
door greeter.
Her physical exam was notable for prominent scleral
icterus, diffuse jaundice, abdominal distension with
dullness in flanks but no tenderness, 3+ pitting edema in
bilateral lower extremities, chronic vitiligo of hands and
chest, palmar erythema, asterixis with mild confusion,
but no spider angiomas or malar rash.
Her labs were significant for iron overload with iron
saturation of 95%, elevated ferritin of 4400 ng/mL,
decreased transferrin to 138 mcg/dL, and iron level
elevated to 185 mcg/dL. She had a macrocytic anemia
with hemoglobin of 9.0 g/dL, MCV 108 and normal B12
and folate.
Labs were negative for CMV, EBV, VZV, HAVAb, HBGAg,
HBVAb, HCVAb, and HIV. Normal AFP (3.7 ng.mL), A1AT
(14 mg/dL), TSH (3.4 uIU/mL), A1c 4.1, and low normal
ceruloplasmin (19mg/dL). Presenting MELD-Na score
was 17 (Cr 0.6, Bili 4.9, INR 1.5, Na 140).
Elevated IgG, but negative ANA and ASMA (ruling out AIH
and PBC). Gene mutations for primary HFE (C282Y and
H63D) were negative.
MRI (Figure 1) was consistent with primary hemochromatosis effecting the non-reticuloendothelial system
(non-RES); involving the liver, but not the spleen or bone
marrow. Additionally, on the dual-sequence MRI
(Figure 2) there is a drop in signal intensity on the image
with the longer echo time10.
Liver biopsy (Figure 3) demonstrated bridging fibrosis
and focal nodularity, stage 3-4. Features of chronic
hepatitis evidenced by mild lobular and portal
inflammation. Iron stain showing 4+ hepatocellular iron
deposit. No evidence of steatohepatitis. No evidence of
portal edema or brisk ductular reaction to support biliary
obstruction.
Despite treatment her condition progressed to ESLD and
she was listed with successful liver transplantation.
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Figure 2: Dual sequence MRI “In Phase and Out of Phase” showing decreased signal
of the liver on the “In Phase” image (left) compared to “Out of phase” image (right)
which is consistent with hemochromatosis. The iron deposition is more severe
in the liver.

Figure 1: Figure 1: T2 weighted MRI showing decreased enhancement of the liver
(darker appearance) but not the spleen, characteristic in iron overload due to primary
hemochromatosis.

DISCUSSION
Hereditary Hemochromatosis (HH) is a disease of iron
overload that is most commonly due to mutations of the
HFE gene. The HFE gene mutation most commonly
involves a tyrosine for cysteine substitution at amino acid
position 282, or protein product C282Y1 . The allele
frequency of C282Y is close to 5% in European
populations according to the 1000 Genomes Project
and explains the large number of European persons with
primary hemochromatosis who are homozygous for
C282Y HFE gene2.
Rarely, there are cases of iron overload consistent with
primary hemochromatosis that do not involve the HFE
gene collectively called non-HFE hemochromatosis3.
These non-HFE genes include hemojuvelin (HJV),
hepcidin (HAMP), transferrin receptor (TFR2) and
ferroportin (SLC40A1). Though most known forms of
primary hemochromatosis have recessive inheritance,
SLC40A1 is recognized as a rare autosomal dominant
inherited genotype that can be associated with a splicing
mutation4. These gene mutations have phenotypes that
range from the severe juvenile forms of iron overload as
in mutations of HJV and HAMP to the milder phenotypes
associated with TFR2 and SLC40A15. Typically, the earlier
onset forms involve severe endocrine and cardiac
manifestations that can result in death by the age of 305.
Notably, ferroportin mutations were first described in
1999 in individuals of Italian and Dutch descent, but
were later observed in gene sequencing of Asian,
American and African populations6,7.
The diagnosis of non-HFE hemochromatosis involves
ruling out secondary causes of iron overload, quantifying
liver iron stores via MRI or liver biopsy, determine the
hereditary nature of the iron overload by genetic testing
(typically for HFE only)8. As mentioned previously, MRI
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Figure 3: Iron stain from our patient showing 4+ hepatocellular iron deposition (left
blue stain). H&E stain demonstrated bridging fibrosis and focal nodularity, stage 3-4
(right pink stain) Features of chronic hepatitis evidenced by mild lobular and portal
inflammation.

did not show involvement of spleen or bone marrow
whereas for hemosiderosis or secondary hemochromatosis, iron deposition would be prominent in these
locations.
Estimates of the prevalence of non-HFE hemochromatosis
were previously about 10%6. To date, 55 HJV cases, 13
HAMP cases, 49 TFR2 cases, and 60 cases of SLC40A1
disease have been reported7. Next-generation sequencing
supports the rarity of these non-HFE pathogenic alleles
with predicted frequencies ranging from 0.00007 to
0.0004. Compare this to the 5% allele frequency of the
C282Y missense substitution as previously noted.
Corresponding predicted frequencies of the genotypes
range from 1 in 556 for SLC40A1 to 1 in 6,000,000 for
TFR2 and as rare as 1 in 181,000,000 for HAMP7.
Heterozygous mutations in SLC40A1 lead to ferroportin
disease and we were surprised to find relatively high
frequencies of SLC40A1 variants classified as pathogenic.
These variants were found at the highest frequencies
among African populations (0.25%) but were also present
in the American (0.039%), East Asian (0.033%), and
non-Finnish European (0.03%) populations7. Non-HFE
HH seems to be more prevalent in southern Europe
compared with northern Europe.
Due to the lack of widely available direct gene
sequencing, these non-HFE genes are not recommended
to be tested unless investigating severe refractory cases8.

The Medicine Forum, Volume 21 | 13 5

2

Park, MD et al.: Diagnosing Non-HFE Hereditary Hemochromatosis

REFERENCES
1. Bacon BR, et al. Diagnosis and Management of Hemochromatosis: 2011
Practice Guideline by the American Association for the Study of Liver
Diseases. Hepatology. 2011;54(1):328-343.
2. Mcdonald CJ, et al. Iron Storage Disease in Asia-Pacific Populations: The
Importance of Non-HFE mutations. Journal of Gastroenterology and
Hepatology. 2013;28(7):1087-1094
3. Lok CY, et al. Iron Overload in the Asian Community. Blood.
2009;114(1):20-25.
4. Zhang W, et al. Type 4B Hereditary Hemochromatosis Associated with a
Novel Mutation in the SLC40A1 Gene. Medicine. 2017;96(38)
5. Pietrangelo A, et al. Non-HFE Hepatic Iron Overload. Seminars in Liver
Disease. 2011;31(3): 302-318.
6. Washington K. Hepatic Iron Deposition: New Observations in Non-HFE
Hemochromatosis. Advances in Anatomic Pathology. 2006;13(6):341-342.
7. Wallace DF, Subramaniam NV. The Global Prevalence of HFE and Non-HFE
Hemochromatosis Estimated from Analysis of next-Generation Sequencing
Data. Genetics in Medicine. 2015;18(6):618-626.
8. Paulo CJDLS, et al. Non-HFE Hemochromatosis. Revista Brasileira De
Hematologia e Hemoterapia. 2012;34(4):311-316.
9. Queiroz-Andrade M, et al. MR Imaging Findings of Iron Overload.
RadioGraphics. 2009;29(6):1575-1589.
10. Merkle EM, Nelson RC. Dual Gradient-Echo In-Phase and Opposed-Phase
Hepatic MR Imaging: A Useful Tool for Evaluating More Than Fatty Infiltration
or Fatty Sparing. RadioGraphics. 2006;26(5):1409-1418.

Volume
21 52020
14 | The
Published
by Medicine
JeffersonForum,
Digital
Commons,

3

